SWOG 1800A-Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

August 06, 2019
https://clinicaltrials.gov/ct2/show/NCT03971474
Cancer - Lung
Principal Investigator: Ding Wang, MD
NSCLC, Non-small cell lung cancer, lung cancer, recurrent lung cancer
Accepting Participants